{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:11:38Z","timestamp":1784308298961,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40258-019-00491-6","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T02:02:55Z","timestamp":1561687375000},"page":"723-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-8837","authenticated-orcid":false,"given":"Ashleigh","family":"McGirr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Van Oorschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Widenmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyosung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijoy","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"issue":"3","key":"491_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1017\/S0950268800004714","volume":"125","author":"M Brisson","year":"2000","unstructured":"Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125(3):651\u201369. \n                    https:\/\/doi.org\/10.1017\/S0950268800004714\n                    \n                  .","journal-title":"Epidemiol Infect"},{"key":"491_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1017\/S0950268801005921","volume":"127","author":"M Brisson","year":"2001","unstructured":"Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305\u201314. \n                    https:\/\/doi.org\/10.1017\/S0950268801005921\n                    \n                  .","journal-title":"Epidemiol Infect"},{"issue":"10","key":"491_CR3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","volume":"81","author":"BP Yawn","year":"2013","unstructured":"Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928\u201330. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e3182a3516e\n                    \n                  .","journal-title":"Neurology"},{"key":"491_CR4","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2014-004833\n                    \n                  .","journal-title":"BMJ Open"},{"issue":"5","key":"491_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jinf.2018.02.001","volume":"76","author":"R Schmidt-Ott","year":"2018","unstructured":"Schmidt-Ott R, Schutter U, Simon J, Nautrup BP, von Krempelhuber A, Gopala K, et al. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged \u226550\u00a0years: a prospective study. J Infect. 2018;76(5):475\u201382. \n                    https:\/\/doi.org\/10.1016\/j.jinf.2018.02.001\n                    \n                  .","journal-title":"J Infect"},{"issue":"11","key":"491_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jpain.2010.02.020","volume":"11","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010;11(11):1211\u201321. \n                    https:\/\/doi.org\/10.1016\/j.jpain.2010.02.020\n                    \n                  .","journal-title":"J Pain"},{"issue":"11","key":"491_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4065\/82.11.1341","volume":"82","author":"BP Yawn","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"491_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin M-J, Bijl M, Franco E, Gaillat J, Clara JG, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109\u201320. \n                    https:\/\/doi.org\/10.1177\/2051013615599151\n                    \n                  .","journal-title":"Ther Adv Vaccines"},{"issue":"16","key":"491_CR9","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","volume":"182","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731\u20136. \n                    https:\/\/doi.org\/10.1503\/cmaj.091711\n                    \n                  .","journal-title":"CMAJ"},{"issue":"1","key":"491_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1155\/2015\/438597","volume":"20","author":"Canadian Pain Society Study Day Participants","year":"2015","unstructured":"Canadian Pain Society Study Day Participants. Safety and effectiveness of the herpes zoster vaccine to prevent postherpetic neuralgia : 2014 update and consensus statement from the Canadian Pain society. Pain Res Manag. 2015;20(1):46\u20137.","journal-title":"Pain Res Manag"},{"issue":"1","key":"491_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s12879-016-1898-z","volume":"16","author":"F Marra","year":"2016","unstructured":"Marra F, Chong M, Najafzadeh M. Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infect Dis. 2016;16(1):589. \n                    https:\/\/doi.org\/10.1186\/s12879-016-1898-z\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"1","key":"491_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12879-017-2185-3","volume":"17","author":"KJ Friesen","year":"2017","unstructured":"Friesen KJ, Chateau D, Falk J, Alessi-Severini S, Bugden S. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia. BMC Infect Dis. 2017;17(1):69. \n                    https:\/\/doi.org\/10.1186\/s12879-017-2185-3\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"1","key":"491_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/1471-2334-14-402","volume":"14","author":"A Gater","year":"2014","unstructured":"Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis. 2014;14(1):402. \n                    https:\/\/doi.org\/10.1186\/1471-2334-14-402\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"1 Suppl","key":"491_CR14","first-page":"S207","volume":"19","author":"GM Sacks","year":"2013","unstructured":"Sacks GM. Unmet need in the treatment of postherpetic neuralgia. Am J Manag Care. 2013;19(1 Suppl):S207\u201313.","journal-title":"Am J Manag Care"},{"issue":"1","key":"491_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","volume":"17","author":"L Varghese","year":"2017","unstructured":"Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):30. \n                    https:\/\/doi.org\/10.1186\/s12877-017-0420-9\n                    \n                  .","journal-title":"BMC Geriatr"},{"key":"491_CR16","unstructured":"National Advisory Committee on Immunization. An Advisory Committee Statement (ACS): update on the use of herpes zoster vaccine. 2014. \n                    https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/healthy-living\/update-use-herpes-zoster-vaccine\/hzv-vcz-eng.pdf\n                    \n                  . Accessed 13 June 2018."},{"key":"491_CR17","unstructured":"Merck Canada Inc. Product monograph: Zostavax. 2017. \n                    https:\/\/pdf.hres.ca\/dpd_pm\/00042265.PDF\n                    \n                  . Accessed 13 June 2018."},{"issue":"6","key":"491_CR18","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, For the Shingles Prevention Study Group, Johnson GR, For the Shingles Prevention Study Group, Schmader KE, For the Shingles Prevention Study Group, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900\u20139. \n                    https:\/\/doi.org\/10.1093\/cid\/ciu918\n                    \n                  .","journal-title":"Clin Infect Dis"},{"key":"491_CR19","unstructured":"GlaxoSmithKline Inc. Product monograph: Shingrix. 2017. \n                    https:\/\/ca.gsk.com\/media\/1350788\/shingrix_pm-2017-10-13.pdf\n                    \n                  . Accessed 13 June 2018."},{"issue":"6","key":"491_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","volume":"34","author":"R Chlibek","year":"2016","unstructured":"Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863\u20138. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.073\n                    \n                  .","journal-title":"Vaccine"},{"issue":"11","key":"491_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, D\u00edez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70\u00a0years of age or older. N Engl J Med. 2016;375(11):1019\u201332. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1603800\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"10","key":"491_CR22","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","volume":"13","author":"D Curran","year":"2017","unstructured":"Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, et al. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Hum Vaccines Immunother. 2017;13(10):2213\u201321. \n                    https:\/\/doi.org\/10.1080\/21645515.2017.1345399\n                    \n                  .","journal-title":"Hum Vaccines Immunother"},{"key":"491_CR23","unstructured":"National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS): updated recommendations on the use of herpes zoster vaccines. 2018. \n                    https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/healthy-living\/updated-recommendations-use-herpes-zoster-vaccines-eng.pdf\n                    \n                  . Accessed 05 Mar 2019."},{"key":"491_CR24","unstructured":"Comit\u00e9 sur l\u2019immunisation du Qu\u00e9bec. Avis sur la pertinence d\u2019ajouter la vaccination contre le zona au Programme qu\u00e9b\u00e9cois d\u2019immunisation. 2018. \n                    https:\/\/www.inspq.qc.ca\/publications\/2381\n                    \n                  . Accessed 22 June 2018."},{"issue":"33","key":"491_CR25","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","volume":"36","author":"D Curran","year":"2018","unstructured":"Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037\u201345. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.005\n                    \n                  .","journal-title":"Vaccine"},{"issue":"20","key":"491_CR26","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","volume":"366","author":"MN Oxman","year":"2012","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2012;366(20):1859\u201369. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1208410\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"491_CR27","unstructured":"Public Health Agency of Canada. Influenza vaccine uptake: results from the 2015\/16 national influenza immunization coverage survey in Canada. 2016. \n                    https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/vaccine-uptake-results-2015-16-national-influenza-immunization-coverage-survey.html\n                    \n                  . Accessed 13 June 2018."},{"issue":"SUPPL. 2","key":"491_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2105\/AJPH.2008.151332","volume":"99","author":"JC Nelson","year":"2009","unstructured":"Nelson JC, Bittner RCL, Bounds L, Zhao S, Baggs J, Donahue JG, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: Results from a vaccine safety datalink study. Am J Public Health. 2009;99(SUPPL. 2):389\u201397. \n                    https:\/\/doi.org\/10.2105\/AJPH.2008.151332\n                    \n                  .","journal-title":"Am J Public Health"},{"key":"491_CR29","unstructured":"CADTH. Guidelines for the economic evaluation of health technologies: Canada, 4th ed. 2017. \n                    https:\/\/www.cadth.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition\n                    \n                  . Accessed 13 June 2018."},{"issue":"22","key":"491_CR30","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1501184\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"7","key":"491_CR31","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359\u00a0years. Clin Infect Dis. 2012;54(7):922\u20138. \n                    https:\/\/doi.org\/10.1093\/cid\/cir970\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"22","key":"491_CR32","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384. \n                    https:\/\/doi.org\/10.1056\/NEJMoa051016\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"491_CR33","unstructured":"Ontario Ministry of Health Long-Term Care. Schedule of benefits physician services under the health insurance act (December 22, 2015 (effective March 1, 2016)) 2016. \n                    http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/\n                    \n                  . Accessed 1 Oct 2017."},{"key":"491_CR34","unstructured":"Statistics Canada. Consumer Price Index, by province (monthly). 2017. \n                    http:\/\/www.statcan.gc.ca\/tables-tableaux\/sum-som\/l01\/cst01\/cpis01a-eng.htm\n                    \n                  . Accessed 13 June 2018."},{"issue":"15","key":"491_CR35","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","volume":"32","author":"R Chlibek","year":"2014","unstructured":"Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745\u201353. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.019\n                    \n                  .","journal-title":"Vaccine"},{"key":"491_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw194.77","author":"D Curran","year":"2016","unstructured":"Curran D, Athan E, Diez-Domingo J, Ghesquiere W, Heineman TC, Lal H, et al. Quality-of-life impact of an investigational subunit-adjuvanted herpes zoster vaccine in adults \u226550\u00a0years of age. Open Forum Infect Dis. 2016. \n                    https:\/\/doi.org\/10.1093\/ofid\/ofw194.77\n                    \n                  .","journal-title":"Open Forum Infect Dis"},{"key":"491_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/BF03405246","volume":"99","author":"M Brisson","year":"2008","unstructured":"Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, healthcare resource use and mortality. Can J Public Health. 2008;99:383\u20136.","journal-title":"Can J Public Health"},{"issue":"12","key":"491_CR38","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","volume":"27","author":"M Najafzadeh","year":"2009","unstructured":"Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27(12):991\u20131004. \n                    https:\/\/doi.org\/10.2165\/11314010-000000000-00000\n                    \n                  .","journal-title":"Pharmacoeconomics"},{"issue":"33","key":"491_CR39","first-page":"729","volume":"63","author":"CM Hales","year":"2014","unstructured":"Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63(33):729\u201331.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"491_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21645515.2018.1509645","volume":"15","author":"D Van Oorschot","year":"2019","unstructured":"Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, et al. Cost-effectiveness of the recombinant zoster vaccine in the German population aged \u226560\u00a0years old. Hum Vaccines Immunother. 2019;15(1):34\u201344. \n                    https:\/\/doi.org\/10.1080\/21645515.2018.1509645\n                    \n                  .","journal-title":"Hum Vaccines Immunother"},{"issue":"4","key":"491_CR41","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/21645515.2018.1558689","volume":"15","author":"D Curran","year":"2019","unstructured":"Curran D, Patterson BJ, Van Oorschot D, Buck PO, Carrico J, Hicks KA, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccines Immunother. 2019;15(4):765\u201371. \n                    https:\/\/doi.org\/10.1080\/21645515.2018.1558689\n                    \n                  .","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"491_CR42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","volume":"178","author":"P Le","year":"2018","unstructured":"Le P, Rothberg MB. Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178(2):248\u201358. \n                    https:\/\/doi.org\/10.1001\/jamainternmed.2017.7431\n                    \n                  .","journal-title":"JAMA Intern Med"},{"issue":"4","key":"491_CR43","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2165\/00019053-199915040-00004","volume":"15","author":"N Mittmann","year":"1999","unstructured":"Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. PharmacoEconomics. 1999;15(4):369\u201376.","journal-title":"PharmacoEconomics"},{"issue":"7","key":"491_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.7326\/M15-0093","volume":"163","author":"P Le","year":"2015","unstructured":"Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50\u00a0years. Ann Intern Med. 2015;163(7):489. \n                    https:\/\/doi.org\/10.7326\/m15-0093\n                    \n                  .","journal-title":"Ann Intern Med"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-019-00491-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-019-00491-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-019-00491-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T02:43:20Z","timestamp":1593225800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-019-00491-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1007\/s40258-019-00491-6","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"28 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: HO-15-15891) and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also covered all costs associated with the development and publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AMG, DVO, RW, LV and DC are employees of the GSK group of companies and DC holds shares in the GSK group of companies. MS and MG are employees of Evidera, a consulting firm that received fees from the GSK group of companies to conduct of these analyses. During the conduct of this study, HJ was also an employee of Evidera.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Shingrix is a trademark of the GSK group of companies. Zostavax is a trademark from Merck Sharp & Dohme Corp.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademark"}},{"value":"AM, DVO, RW, MS and DC participated to the conception of the analysis and adaptation of the model. All authors were involved in the data collection. AM, DVO, MS, HJ and DC performed the analysis. AM, DVO, RW, MS, HJ, LV and DC participated to the interpretation of the data. All authors had full access to the data, reviewed the manuscript and approved the final version of the paper for submission.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"GSK makes available anonymized individual participant data and associated documents from interventional clinical studies which evaluate medicines, upon approval of proposals submitted to . To access data for other types of GSK sponsored research, for study documents without patient-level data and for clinical studies not listed, please submit an enquiry via the website.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}